University of Arkansas: Multiple Myeloma trials
The registry lists 56 Multiple Myeloma studies with University of Arkansas as lead sponsor. 1 are open to participants now and 23 have results posted.
Phase 1 7Phase 2 32Phase 3 12No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple MyelomaNot yet recruitingNCT07029776Phase 2
- UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib TreatmentCompletedNCT02499081Phase 2Results posted
- UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusCompletedNCT02192775Phase 2Results posted
- UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionTerminatedNCT02128230Phase 2Results posted
- UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple MyelomaCompletedNCT01884688Phase 2Results posted
- UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple MyelomaCompletedNCT01621672Phase 3Results posted
- Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell MobilizationTerminatedNCT01449539Not applicableResults posted
- UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaCompletedNCT01313897Phase 2Results posted
- Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple MyelomaCompletedNCT01177735Phase 2Results posted
- Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01062230Phase 2Results posted
- Preemptive Strike With Bortezomib in Multiple Myeloma PatientsTerminatedNCT00657553Phase 3Results posted
- UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple MyelomaCompletedNCT00580372Phase 2Results posted
- 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACECompletedNCT00577512Phase 2Results posted
- Effects of Exercise in Combination With Epoetin AlfaCompletedNCT00577096Not applicableResults posted
- UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideTerminatedNCT00574080Phase 3Results posted
- Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2TerminatedNCT00573391Phase 3Results posted
- UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicableResults posted
- Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00128921Phase 2Results posted
- UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma PatientsTerminatedNCT00113919Phase 1/2Results posted
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedNCT00090493Phase 2/3Results posted
- DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE ConsolidationCompletedNCT00083915Phase 3Results posted
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyCompletedNCT00083551Phase 3Results posted
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083382Phase 2Results posted
- UARK 2003-33, Total Therapy IIICompletedNCT00081939Phase 2Results posted
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnNCT03003728Phase 2
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnNCT03000634Phase 2
- UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD CombinationWithdrawnNCT02578121Phase 2
- UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibWithdrawnNCT02140840Phase 2
- A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered VemurafenibWithdrawnNCT02115035Phase 1/2
- Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant RecipientsCompletedNCT02035189
- Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple MyelomaCompletedNCT01622582
- A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) PatientsStatus unknownNCT01314625
- Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma SubjectsTerminatedNCT01018927
- UARK 2009-32 Compassionate Use Study of CarfilzomibNo longer availableNCT00999414
- Panobinostat/Velcade in Multiple MyelomaTerminatedNCT00891033Phase 1
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionActive, not recruitingNCT00869232Phase 2
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaActive, not recruitingNCT00734877Phase 3
- UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological MalignanciesWithdrawnNCT00578045Phase 1
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)WithdrawnNCT00577668Phase 2
- Therapeutic Research in Multiple MyelomaCompletedNCT00572338
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total TherapyActive, not recruitingNCT00572169Phase 3
- UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple MyelomaCompletedNCT00113932Phase 2
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory PatientsCompletedNCT00111748Phase 3
- Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
- Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell TransplantCompletedNCT00089453Phase 1
- Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage TherapyCompletedNCT00083902Phase 2
- D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple MyelomaCompletedNCT00083876Phase 3
- DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation RelapseCompletedNCT00083681Phase 2
- Anti-Angiogenesis Therapy Using Thalidomide in Multiple MyelomaCompletedNCT00083577Phase 2
- Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or IntranodallyCompletedNCT00083538Phase 2
- Study of Combination PS-341 and Thalidomide in Multiple MyelomaCompletedNCT00083460Phase 1
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083408Phase 2
- An Open Protocol for the Compassionate Use of ThalidomideCompletedNCT00081757Phase 1/2
- Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's DiseaseCompletedNCT00002652Phase 2